Arbutus Biopharma
Presence
Arbutus Biopharma is one of the...
Arbutus Biopharma is a company listed under the stock ticker ABUS (CA).
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Arbutus Biopharma
- Daniel Burgess, Director
- Keith Manchester, Independent Director
- Richard Henriques, Non-Executive Director
Popular executive movements at Arbutus Biopharma
- Michael McElhaugh who is Chief Operating Officer, will be promoted to Interim President and Chief Executive Officer on Jan. 1, 2024 (posted on November 8 2023).
- William Collier, Director, President and Chief Executive Officer, will retire on Dec. 31, 2023 (posted on November 8 2023).
Create your alert
to follow the executive moves at Arbutus Biopharma.
Pharmaceuticals
Arbutus Biopharma has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Arbutus Biopharma
- RSS News Feeds | Arbutus Biopharma Corporation
- Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference | Arbutus Biopharma Corporation
- Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference | Arbutus Biopharma Corporation
- Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg | Arbutus Biopharma Corporation
- Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference | Arbutus Biopharma Corporation
- Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection | Arbutus Biopharma Corporation
- Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Arbutus Biopharma Corporation
- Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference | Arbutus Biopharma Corporation
- Arbutus to Report Second Quarter 2020 Financial Results | Arbutus Biopharma Corporation
- Press Releases | Arbutus Biopharma Corporation
- View more press releases Close
Social media about Arbutus Biopharma
- Arbutus Biopharma on Wikipedia, Google News & Yahoo Finance
- Arbutus Biopharma on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Frank Torti 
Call Arbutus Biopharma at +1 604...
